"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at the timing of radiotherapy for rectal cancer (CR07)
This trial compared radiotherapy before surgery with radiotherapy after surgery for cancer of the back passage (rectum).
The aim of this trial was to find out if it was better to have radiotherapy before or after surgery. Patients having radiotherapy after surgery could be given a small dose of a chemotherapy drug called 5FU, as this helps the radiotherapy to work better (chemoradiotherapy).
Summary of results
The research team found that it was better to give radiotherapy before surgery to lower the chance of rectal cancer coming back in the area it first started (
It was a randomised trial and recruited 1,350 people
- Half went into the ‘radiotherapy before surgery’ group
- Half went into the ‘chemoradiotherapy after surgery’ group
Not everyone in the second group had chemoradiotherapy. This depended on different factors, including whether or not they had
When the research team analysed their results, they had followed the progress of those taking part for an average of 4 years. They found that
- 330 people had died (157 in the radiotherapy before surgery group and 173 in the chemoradiotherapy after surgery group)
- The cancer had come back locally in more people in the chemoradiotherapy after surgery group (72 people) than in the other group (27 people)
- 3 years after treatment, more people were alive and cancer free (disease free survival) in the group having radiotherapy before surgery (77.5%) compared to the group having it after surgery (71.5%)
- The number of people alive, with or without any signs of cancer, (overall survival) was the same in both groups
The research team did look at the side effects of radiotherapy before and after surgery, and how it affects patients’ quality of life, but they will publish these results separately.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr David Sebag-Montefiore
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer